Consistent with these findings, our analysis of publicly available data sets has shown that the expression of CCNG2 is reduced in metastatic tumors compared to primary tumors in a variety of cancer types and in particular in melanoma. This evidence concerns the gene CCNG2 and metastatic neoplasm.